LT-HSCs (Fig. 1a,b) . To test the responsiveness of HSCs to PAR1, we injected mice with thrombin to mimic stress and injury. Active thrombin entered the bone marrow rapidly, by 5 min after injection, then declined in bone marrow activity to baseline levels by 30 min after injection (Fig. 1c) , at which time thrombin-antithrombin (TAT) complexes had accumulated in the bone marrow ( Supplementary Fig. 1b ).
Thrombin injection also induced a rapid, PAR1-dependent increase in the number of circulating leukocytes (Supplementary Fig. 1c ) and immature progenitors ( Fig. 1d and Supplementary Fig. 1d ), which functionally expressed PAR1 (Fig. 1d) . Thrombin injection led to an increase in the number of functional LT-HSCs in the blood, as assessed by a long-term competitive reconstitution assay (Fig. 1e) . Notably, F2r −/− mice, which are deficient in PAR1, had elevated baseline levels of circulating immature Lin − Sca-1 + c-Kit + (LSK) cells; these levels were not reduced by PAR1 inhibition, confirming the specificity of PAR1 antagonism (Supplementary Fig. 1e ). Upregulation of surface PAR1 levels was also detected on bone marrow LSK progenitors 1 h after thrombin injection ( Supplementary Fig. 1f ), probably owing to enhanced recycling of PAR1 from intracellular pools 25 , in agreement with data for human mobilized CD34 + cells 26 . Thrombin mobilized HSPCs in F2rl1 −/− mice, which are deficient in PAR2, but not in F2r −/− mice ( Fig. 1f) . Bone marrow chimeras revealed that both hematopoietic (donor) as well as stromal and endothelial (recipient) F2r were essential for thrombin-induced HSPC recruitment (Fig. 1g) .
To delineate the stromal contribution for HSC recruitment induced by thrombin treatment, we first confirmed PAR1 expression by bone marrow stromal cells (Fig. 1h) , in line with previous work demonstrating regulation of bone marrow mesenchymal stem cells by thrombin-PAR1 (ref. 27 ). Next, we studied the relationship of PAR1 to CXCL12-CXCR4 signaling. Thrombin treatment decreased CXCL12 reactivity in bone marrow (Supplementary Fig. 2a ) and induced a PAR1-dependent increase in CXCL12 concentrations in the blood (Supplementary Fig. 2b ), thereby enhancing CXCR4-dependent HSPC recruitment ( Supplementary Fig. 2c-e) 6, 15, [28] [29] [30] . Moreover, thrombin induced PAR1-dependent CXCL12 secretion from cultured bone marrow stromal cells (Fig. 1i,j) . CXCL12-induced directional migration of bone marrow progenitors was inhibited by a PAR1 antagonist (Supplementary Fig. 2f ) and the migration efficiency of F2r −/− HSPCs toward CXCL12 was lower than that of control HSPCs (Supplementary Fig. 2g ). Taken together, these results demonstrate a major role for the thrombin-PAR1 pathway in modulating bone marrow CXCL12-CXCR4 chemokine signaling, leading to stressinduced HSPC recruitment to the bloodstream.
Thrombin-PAR1 signaling induces EPCR shedding and HSC mobilization
Because bone marrow LT-HSCs highly express EPCR 18 , we analyzed whether thrombin-induced LT-HSC mobilization results in the appearance of circulating EPCR + HSCs. HSCs expressed EPCR in the bone marrow but, surprisingly, not in the peripheral blood; steady state or thrombin-mobilized circulating HSPCs lacked EPCR expression (Fig. 2a,b and Supplementary Fig. 3a) . Thrombin-induced HSC recruitment to the bloodstream was associated with a PAR1-dependent reduction in the percentage of primitive bone marrow EPCR + LSK cells (Fig. 2c) but did not affect the immature LSK pool size (Supplementary Fig. 3b ). As thrombin stimulates EPCR shedding from the endothelial cell surface 31 , we measured soluble EPCR (sEPCR) levels in the bone marrow after thrombin treatment. Bone marrow fluid obtained from thrombin-treated mice had increased levels of sEPCR (Fig. 2d,e) . Confirming the PAR1 dependence of sEPCR release, thrombin failed to induce EPCR shedding above baseline levels in F2r −/− mice (Fig. 2e) . Moreover, thrombin treatment of lineage-depleted bone marrow cells led to sEPCR release (Fig. 2f) .
Endothelial EPCR shedding is mediated by tumor necrosis factor-α-converting enzyme (TACE, also known as ADAM17) 32 ( Supplementary Fig. 3c ). We found that bone marrow EPCR + HSCs express TACE, in particular its nonactivated precursor, as detected by an antibody to the inhibitory prodomain (Supplementary Fig. 3d ). Mirroring EPCR expression, TACE prodomain was present on primitive bone marrow HSCs but not on circulating LSK cells expressing the SLAM family of HSC markers (LSK SLAM cells) ( Supplementary  Fig. 3e ). Treatment of mice with a TACE monomeric prodomainspecific inhibitor 33 prevented thrombin-induced EPCR shedding in bone marrow (Fig. 2g ) and limited stem cell mobilization (Fig. 2h) . Taken together, these results demonstrate thrombin-dependent EPCR shedding from bone marrow LT-HSCs and suggest a role for TACE in stem cell recruitment.
EPCR-PAR1 signaling promotes LT-HSC retention in bone marrow
These findings, which show that EPCR shedding from bone marrow LT-HSCs is associated with stem cell recruitment, suggest a functional role for EPCR in LT-HSC retention in the bone marrow. To address this possibility, we first confirmed that components of the EPCR-PAR1 system are expressed in the bone marrow. The thrombinthrombomodulin (thrombin-TM) complex converts protein C to its activated form, aPC 34 ( Supplementary Fig. 1a) , and previous work has shown that TM is expressed by bone marrow endothelial cells and by mature and immature hematopoietic cells 24 . We confirmed TM expression on bone marrow vascular endothelial (VE)-cadherin + blood vessels (Supplementary Fig. 4a ). TM-expressing blood vessels were located in close proximity to EPCR + LT-HSCs, which were also positive for TM ( Fig. 3a and Supplementary Fig. 4b,c) . In support of the concept that aPC is generated locally in the bone marrow microenvironment, TM + blood vessels expressed aPC ( Supplementary  Fig. 4d ), and EPCR + stem cells were located adjacent to aPC-enriched endothelial areas (Fig. 3b) . Expression of TM by EPCR + LT-HSCs (Supplementary Fig. 4e ) suggests that aPC generation takes place not only in the stromal compartment of the bone marrow microenvironment but also in HSCs themselves, in line with previous work suggesting aPC generation in mature and immature hematopoietic cells 24 . Similarly to EPCR, TM was expressed by bone marrow LT-HSCs but not circulating stem cells (Supplementary Fig. 4f) .
We next studied EPCR function in LT-HSCs using adhesion assays, in which bone marrow cells were allowed to adhere to plates coated with CXCL12 and fibronectin. We found that a large percentage of adherent cells (but only few nonadherent cells) were primitive EPCR + LSK cells (Supplementary Fig. 5a ). Adhesion of EPCR + LSK cells was reduced by a neutralizing anti-EPCR antibody that blocks aPC binding and other EPCR signaling functions 35 , and adhesion was markedly enhanced by aPC stimulation (Supplementary Fig. 5b ). Conversely, bone marrow LSK cells that migrate toward CXCL12 were mostly EPCR − (Supplementary Fig. 5c ).
Deletion of the gene encoding EPCR (Procr) in mice leads to embryonic lethality 36 . Therefore, we used mice genetically modified to have a severe targeted deficiency in EPCR owing to integration of exogenous DNA elements into the 5′ untranslated region of the Procr gene 37 . These mice (here referred to as Procr low ) are viable and had markedly reduced surface expression of EPCR on bone marrow LSK cells (Supplementary Fig. 6a ). Procr low mice had higher levels of circulating leukocytes and HSPCs in the blood a r t i c l e s nature medicine VOLUME 21 | NUMBER 11 | NOVEMBER 2015 1 3 0 9
( Fig. 3c and Supplementary Fig. 6b,c) and reduced numbers of primitive bone marrow HSCs (Fig. 3d) than did wild-type control mice. Consistent with a defect in HSPC retention, Procr low bone marrow LSK progenitor cells had greater migration capacity toward CXCL12 and decreased adhesion to immobilized CXCL12-fibronectin ( Supplementary Fig. 6d,e) . Reduced bone marrow retention of HSCs in Procr low mice was associated with an increased frequency of HSCs in the spleen (Supplementary Fig. 6f ). Similarly to Procr low mice, F2r −/− mice showed higher numbers of HSPCs in the circulation (Fig. 3e) and reduced bone marrow HSC retention (Fig. 3f) , with no significant changes in the number of HSCs in the spleen (Supplementary Fig. 6g ). Thbd Pro/Pro mice are characterized by a mutation in the gene encoding TM that impairs thrombin binding to TM, limiting aPC generation and thereby causing chronically deregulated control of thrombin generation 38 . We found that Thbd Pro/Pro mice also show higher levels of HSPCs in the blood circulation, whereas aPC treatment of these mice partially reversed this phenotype (Supplementary Fig. 6h) . Consistent with the idea that increased HSPC egress in Thbd Pro/Pro mice is due to a reduction in aPC generation, TM expression on bone marrow LT-HSCs was similar between wild-type and Thbd Pro/Pro mice, and EPCR expression on bone marrow HSCs was slightly higher in Thbd Pro/Pro than in wild-type mice (Supplementary Fig. 6i,j) .
To functionally test the role of EPCR in LT-HSC bone marrow retention, we performed long-term competitive hematopoietic reconstitution experiments with bone marrow from Procr low mice. Compared to wild-type HSCs, bone marrow HSCs from Procr low mice showed markedly reduced competition with wild-type bone marrow cells (Fig. 3g) . Furthermore, functional antagonism of EPCR reduced the competitive long-term ability of HSCs to repopulate irradiated bone marrow (Fig. 3h) . Taken together, these results indicate that a functional aPC-EPCR-PAR1 signaling pathway is present in the bone marrow microenvironment that regulates EPCR + LT-HSC retention and long-term repopulation potential in the bone marrow.
aPC-EPCR-PAR1 signaling regulates HSC adhesion
In LT-HSCs, regulation of Cdc42 activity and its polar distribution is crucial for cell adhesion and bone marrow repopulation potential 39, 40 .
We found a random distribution of Cdc42 in immature bone marrow EPCR − LSK cells, whereas primitive EPCR + LSK cells showed a polar Cdc42 distribution (Fig. 4a) . Blockade of ligand binding to EPCR induced Cdc42 depolarization (Fig. 4b) , and bone marrow PAR1-deficient F2r −/− EPCR + Sca-1 + c-Kit + (SK) SLAM cells also lacked polar Cdc42 distribution (Supplementary Fig. 7a ). Cdc42 polarity correlates with low Cdc42 activity in HSCs 41 . Bone marrow EPCR + HSCs expressed lower levels of active Cdc42 (Cdc42-GTP) than did EPCR − SK SLAM cells ( Fig. 4c and Supplementary Fig. 7b ). Moreover, EPCR blockade abrogated Cdc42 polarity ( Fig. 4b) and increased Cdc42-GTP levels ( Fig. 4d and Supplementary Fig. 7c ). Accordingly, LSK SLAM bone marrow cells from Procr low mice showed higher Cdc42 activity and less adhesion than did LSK SLAM bone marrow cells from wild-type mice; the effect on adhesion was reversed by in vitro treatment with the Cdc42 inhibitor CASIN (Supplementary Fig. 7d,e) . These data indicate that EPCR signaling controls Cdc42 polarity and activity, and thereby cell adhesion, in HSCs.
Next, we found that the adhesion molecule integrin α 4 β 1 (VLA4), which binds fibronectin and vascular cell adhesion molecule 1 (VCAM-1) and is crucial for bone marrow HSC retention 1, 42 , was expressed at higher levels by bone marrow EPCR + LSK cells than by EPCR − LSK cells ( Fig. 4e and Supplementary Fig. 8a ) or circulating primitive progenitors (Supplementary Fig. 8b ). Accordingly, VLA4 had higher affinity for ligand binding on bone marrow EPCR + HSCs than on bone marrow EPCR − HSCs (Supplementary Fig. 8c) . Notably, aPC treatment increased VLA4 affinity on wild-type, but not Procr low , bone marrow LT-HSCs in an EPCR-dependent manner (Fig. 4f,g ), despite similar surface expression of VLA4 (Fig. 4h) . In addition, F2r −/− bone marrow SK SLAM stem cells had normal VLA4 expression, but their VLA4 affinity was lower than that of wild-type stem cells (Fig. 4i) . Cdc42 inhibition by CASIN increased the VLA4 affinity of bone marrow HSCs (Supplementary Fig. 8d) , linking Cdc42 function to affinity modulation of VLA4. The effect of CASIN on VLA4 affinity was specific, as a conformational antibody to β 1 integrins, which are generally crucial for HSC function and bone marrow retention 43, 44 , bound similarly to wild-type bone marrow HSCs with and without CASIN treatment, and it also bound similarly to wild-type, Procr low and F2r −/− bone marrow HSCs ( Supplementary Fig. 8e-g ).
A neutralizing anti-VLA4 antibody mobilizes LT-HSCs to the blood 42 , indicating that VLA4 is crucial for HSC retention in the bone marrow. We found that low surface expression of CXCR4 on bone marrow EPCR + HSCs was rapidly upregulated by EPCR neutralization ( Supplementary  Fig. 8h ). Moreover, repeated in vivo administration of a neutralizing EPCR antibody mobilized HSCs to the blood, similarly to VLA4 blockade (Fig. 4j) . Notably, blockade of EPCR or VLA4 led to mobilization of LT-HSCs that retained EPCR expression in the blood circulation (Fig. 4j) . Taken together, these data show that aPC-EPCR-PAR1 signaling leads to a low level of Cdc42 activity, increased VLA4 affinity and retention of EPCR + LT-HSCs in the bone marrow.
NO production overcomes HSC retention in the bone marrow We next sought to understand the mechanism by which thrombin-PAR1 signaling induces EPCR shedding to counteract EPCR-dependent adhesion. NO signaling is essential for the initiation of hematopoiesis during embryonic development 45, 46 , and endothelial nitric oxide synthase (eNOS, encoded by Nos3) activity by bone marrow stromal cells is essential for the mobilization of endothelial progenitor cells 47 . NO production is activated by eNOS phosphorylation at Ser1177 and negatively regulated by eNOS phosphorylation at Thr495 (ref. 48) . We found that circulating SLAM cells contain higher intracellular NO levels than do bone marrow-retained HSC (Fig. 5a) . Notably, thrombin injection rapidly increased NO levels in bone marrow HSCs ( Supplementary  Fig. 9a ) and eNOS phosphorylation at Ser1177 in immature LSK cells (Fig. 5b,c) . The specificity of the NO probe was demonstrated by pretreatment of HSCs with the NOS inhibitor l-NAME ( Supplementary  Fig. 9b ). Pharmacological inhibition of NO generation by l-NAME markedly reduced thrombin-induced HSPC recruitment and prevented EPCR shedding by bone marrow LT-HSCs (Fig. 5d) .
Next, we generated chimeric Nos3 −/− mice, which are deficient in NO synthase 3 (eNos), in either hematopoietic (donor) or stromal cells (recipient). In support of the concept that eNOS has an intrinsic role in HSCs, thrombin injection in chimeric mice with hematopoietic deficiency of Nos3 failed to increase circulating LSK levels or to diminish the percentage of EPCR + LSK cells in bone marrow (Fig. 5e) . Thrombin also failed to mobilize LSK cells in Nos3 −/− mice (Supplementary Fig. 9c ). Pharmacological elevation of NO levels in Nos3 −/− mice with the NO donor SNAP induced LSK cell mobilization and decreased the percentage of bone marrow EPCR + LSK cells (Supplementary Fig. 9d,e) . Accordingly, injection of SNAP into wild-type mice rapidly mobilized immature LSK cells and reduced EPCR expression on bone marrow LSK cells (Fig. 5f) . Fig. 9f,g ). Moreover, the rapid, thrombin-induced disappearance of TACE prodomain expression by primitive bone marrow HSCs was blocked by l-NAME pretreatment ( Supplementary  Fig. 9h ), suggesting NO-dependent TACE activation. Thrombin injection rapidly induced loss of the polar pattern of Cdc42 distribution in bone marrow EPCR + HSCs and reduced EPCR staining intensity (Fig. 5g) , indicative of EPCR shedding. NOS inhibition with l-NAME prevented the thrombin-induced increase in Cdc42-GTP content (Fig. 5h) , whereas treatment with SNAP elevated Cdc42-GTP activity and reduced VLA4 affinity on bone marrow LT-HSCs (Fig. 5i) . These results position thrombin-PAR1 signaling upstream of NO production, which in turn promotes Cdc42 activity and TACE-mediated EPCR shedding from bone marrow stem cells.
TACE inhibition abrogated the effects of SNAP on LSK cell mobilization and EPCR expression on bone marrow HSCs (Supplementary

aPC-EPCR-PAR1 signaling restricts NO production in bone marrow HSCs
As our data indicate that thrombin-PAR1 signaling overcomes EPCRmediated bone marrow LT-HSC retention by elevating NO levels, we measured NO content in bone marrow LT-HSCs. We found that EPCR + LSK cells had lower intracellular NO levels than did EPCR − LSK cells (Fig. 6a) . Notably, NO content was elevated in bone marrow LSK SLAM cells from Thbd Pro/Pro mice ( Supplementary Fig. 10a ), which have impaired aPC generation, as well as in bone marrow HSCs from F2r −/− mice (Supplementary Fig. 10b) . Blockade of EPCR function increased intracellular NO content in primitive HSCs (Fig. 6b) . Moreover, Procr low bone marrow LT-HSCs had higher baseline intracellular NO levels than did wild-type LT-HSCs, and treatment with aPC reduced NO content in wild-type but not Procr low bone marrow LT-HSCs (Fig. 6c) . Most EPCR − and EPCR + SLAM HSCs in the bone marrow showed low levels of eNOS Ser1177 phosphorylation; however, the majority of EPCR + SLAM HSCs and only a minority of EPCR − SLAM HSCs showed inhibitory eNOS Thr495 phosphorylation (Supplementary Fig. 10c,d ). aPC treatment of SK SLAM HSCs increased eNOS phosphorylation at Thr495 and caused gradual dephosphorylation at Ser1177 (Fig. 6d) in a PAR1-dependent manner (Supplementary Fig. 10e,f) . Moreover, neither chloromethylketone-inactivated aPC nor the alternative EPCR ligand factor VIIa induced eNOS Thr495 phosphorylation in bone marrow SLAM LSK cells (Fig. 6e) . Thus, proteolytic aPC-EPCR-PAR1 signaling imposes inhibitory eNOS phosphorylation and thereby limits NO generation in bone marrow EPCR + LSK cells. Next, to suppress NO generation in the absence of EPCR signaling, we treated chimeric mice reconstituted with Procr low bone marrow with l-NAME. This intervention reduced the levels of circulating LSK cells (Fig. 6f) . In vitro, l-NAME treatment normalized the behavior of Procr low LSK cells in adhesion and migration assays (Fig. 6g) . As EPCR + HSCs possess the highest long-term repopulation potential [18] [19] [20] [21] , we tested whether limiting NO levels in vivo can increase LT-HSC repopulation potential. Prolonged l-NAME treatment preferentially reduced immature LSK cell egress to the blood and induced preferential increase of primitive bone marrow EPCR + LSK cells (Fig. 6h) and quiescent CD34 − LSK cells ( Supplementary  Fig. 11a) . Egress of maturing leukocytes (Supplementary Fig. 11b) , bone marrow cellularity and total immature LSK progenitor cell percentage (Supplementary Fig. 11c,d) were minimally affected. Competitive long-term bone marrow reconstitution assays revealed increased multilineage repopulation after l-NAME pretreatment of donor mice (Fig. 6i and Supplementary Fig. 11e) , with balanced myeloid and lymphoid reconstitution (Supplementary Fig. 11f ) and higher levels of donor-type EPCR + LT-HSCs (Supplementary Fig. 11g) . Of note, when we transplanted half the cell dose of donor bone marrow cells from l-NAME pretreated mice, we still observed higher reconstitution levels than with the full cell dose of bone marrow cells from mice pretreated with PBS (Fig. 6i) . Similarly, treatment of mice with aPC reduced mature and immature leukocyte egress ( Supplementary  Fig. 12a,b) , preferentially increased quiescent CD34 − LSK and primitive bone marrow EPCR + LSK cell populations ( Supplementary  Fig. 12c-f ) and also increased competitive bone marrow reconstitution (Supplementary Fig. 12g) .
Retention of HSCs in supportive stromal niches in the bone marrow is essential to maintain HSC quiescence and to protect HSCs from myeloablation 3 . We therefore evaluated the role of EPCR-PAR1 signaling in protecting mice from mortality induced by the chemotherapy drug 5-FU. Treatment with SNAP sensitized mice to 5-FU-induced death (Fig. 6j) , indicating that suppression of NO production has a crucial role in survival after myeloablation. F2r −/− mice and mice treated with a neutralizing anti-EPCR antibody were also more susceptible to mortality induced by 5-FU treatment than were wild-type mice (Fig. 6j) . These results suggest that aPC-EPCR-PAR1 signaling, by limiting NO production, retains EPCR + LT-HSCs in the bone marrow and protects them from chemotherapy insult.
DISCUSSION
Here we describe a new role for factors involved in coagulation and inflammation pathways as regulators of LT-HSC function within the bone marrow microenvironment. Our results reveal that, beyond its role in hemostasis, PAR1 acts through distinct signaling cascades to promote or inhibit NO production by LT-HSCs. PAR1 retains bone marrow EPCR-expressing HSCs through suppression of NO production and mediates stem cell recruitment through elevation of NO levels, EPCR shedding and activation of Cdc42 (Supplementary Fig. 13a,b) .
EPCR was recently identified as a stem cell marker in various organs 11 , including murine fetal liver and adult bone marrow LTHSCs [18] [19] [20] [21] and mammary stem cells 49 , and its function is crucial for breast cancer stem cell phenotypes and tumor progression 50 . We found that EPCR ligand-dependent signaling occurs within a TM-and aPC-enriched endothelial microenvironment in the bone marrow. Consistent with our findings, mice harboring a Procr mutation that disables all ligand binding to EPCR, including binding by aPC, show bone marrow failure and splenomegaly 51 . We further show that EPCR-PAR1 signaling functionally regulates anchorage and bone marrow retention of LT-HSCs by restricting NO production and Cdc42 activity, leading to increased VLA4 affinity ( Supplementary  Fig. 13a ). Although the ultimate consequence of the endothelialto-hematopoietic transition during ontogeny is downregulation of the endothelial program in blood-forming stem cells and mature leukocytes, bone marrow-retained LT-HSCs preserve expression of some endothelial genes, such as those encoding EPCR [18] [19] [20] [21] and Von Willebrand factor 52 . Our findings indicate that LT-HSCs in the adult bone marrow preserve endothelial expression of TM and EPCR, which ultimately maintain stem cells with low NO levels, protecting them from DNA damaging agents and cell death 20, 24 .
On the basis of these and previous findings 24 , we propose that the homeostatic bone marrow stem cell niche represents a TMenriched microenvironment that can initiate local aPC generation, which functionally retains long-term repopulating EPCR + stem cells. Similarly to endothelial cells, bone marrow EPCR + LT-HSCs express surface TM, implying the possibility of autocrine aPC generation. Recently, megakaryocytes were found to negatively regulate bone marrow HSC proliferation via secretion of platelet factor 4 (PF4) 53, 54 . PF4 also supports TM-dependent aPC generation 55 , suggesting that megakaryocytes may participate in the TM + niche for EPCR + stem cells, enhancing aPC generation and thereby contributing to LT-HSC bone marrow retention and protection. Indeed, under chemotherapeutic stress conditions, PF4 secretion by megakaryocytes promotes HSC regeneration 53 , in agreement with our results that aPC-EPCR signaling restricts NO production, increases bone marrow LT-HSCs and protects them from chemotherapy insult.
A previous study reported a rare population of radiationresistant α-SMA + COX2 + macrophages, which maintain bone marrow LT-HSCs and protect them from inflammatory insult by limiting reactive oxygen species production via prostaglandin E2 secretion 56 . Here we reveal that limitation of NO production via aPC-EPCR-PAR1 signaling induces LT-HSC retention in the bone marrow and protection from chemotherapy-induced mortality. PAR1 signaling in bone marrow LT-HSCs regulates NO generation through balanced control of eNOS phosphorylation at two regulatory sites ( Supplementary  Fig. 13c ). aPC-EPCR-PAR1 signaling leads to increased eNOS phosphorylation at the negative regulatory site Thr495 and reduced phosphorylation at the positive regulatory site Ser1177, maintaining bone marrow LT-HSCs with low NO levels. Low NO levels limit, in turn, Cdc42 activity, which is required for LT-HSC adhesion and bone marrow retention. Similarly to breast cancer stem cells, where EPCR regulates proliferation on matrices that engage VLA4 (ref. 50) , bone marrow LT-HSCs exhibit higher VLA4 affinity owing to aPC-EPCR-PAR1 signaling. Our results are consistent with previous findings implicating elevated Cdc42 activity in the reduced function of aged HSCs, which show attenuation of Cdc42 polarity 40, 41 , a feature associated with loss of cell adhesion and function 57, 58 .
LT-HSCs must exit quiescence and overcome bone marrow retention to ensure homeostatic and stress-induced blood cell production. Our findings reveal that thrombin and NO generation are required to address the changing demands for new blood cell production. Physiological stress, inflammation and cytokine-induced mobilization transiently increase thrombin generation 59 . Our model suggests that increased thrombin levels directly activate PAR1 signaling cascades in bone marrow LT-HSCs and in stromal cells (Supplementary Fig. 13b ), inducing stem cell egress and recruitment to the blood circulation as part of host defense and repair. Thrombin-PAR1 signaling shifts eNOS phosphorylation at its activating site Ser1177, initiating NO production, which enables bone marrow LT-HSC migration and recruitment. Notably, Nos3 −/− mice did not mobilize stem cells in response to thrombin stimulation. Consistent with our findings, signaling driven by NO production potentiates stem cell migration, leading to hematopoiesis during mouse fetal development 45, 46, 60 . Conversely, we found that reducing NO levels preferentially retains the undifferentiated LT-HSC pool in the bone marrow via adhesive interactions with stromal cells.
We found that thrombin-dependent shedding of EPCR by TACE 32 overcomes LT-HSC retention in the bone marrow, such that circulating HSPCs in the blood lack EPCR expression ( Supplementary  Fig. 14) . As low levels of thrombin can initiate aPC production 34 , it is conceivable that homeostatic, low levels of thrombin regulate LT-HSC retention in the bone marrow by generating aPC, whereas stress-induced, transiently increased thrombin levels induce LT-HSC recruitment. Bone marrow-retained LT-HSCs and HSPCs in the circulation can be functionally distinguished by differences in intracellular NO content (Supplementary Fig. 14) . Thrombinmobilized HSCs maintain their long-term repopulation potential and re-express EPCR in the bone marrow after transplantation. Future studies at the single-cell level will reveal whether these cells can revert from a state with high NO levels back to a bone marrow-retained stem cell with low intracellular NO content. Although our results mainly focus on the major role of eNOS in the maintenance of bone marrow LT-HSCs, it should be noted that inducible NOS (iNOS) and neuronal NOS (nNOS), which are expressed at low levels by LT-HSCs, might also be involved and regulated by PAR1 signaling. Previous work demonstrated that iNOS knockdown in zebrafish does not affect the runx1-cmyb gene complex, which regulates the differentiation of HSCs to mature blood cells 45 .
Our results reveal that PAR1 signaling, under the direction of thrombin and aPC, acts as a switch for stem cell function. This switch dictates localization and activation states, regulating stem cell retention in the bone marrow, susceptibility to chemotherapy insult, migration and repopulation potential. Harnessing of this switch has the potential to improve clinical stem cell mobilization and transplantation protocols as well as the resistance of stem cells to chemotherapy.
METHODS
Methods and any associated references are available in the online version of the paper. calcium chloride and magnesium chloride (PBS +/+ ). Cells were resuspended in 300 µl PBS +/+ for analysis by flow cytometry with negative control samples stained with LDV-FITC in the presence of EDTA.
Colony-forming assays (CFU-C).
Peripheral blood MNCs were isolated by Ficoll (Lymphoprep) separation and were seeded (2 × 10 5 cells/mL) in semisolid cultures supplemented with EPO (2 U/ml, obtained from Ortho BioTech, Don Mills, Canada), IL-3, GM-CSF (both obtained from Kirin Brewery Company, Tokyo, Japan) and SCF (PeproTech) as previously described 28 . Colonies, reflecting colony-forming unit cells (CFU-C), were scored 7 d after plating and presented as CFU-C/ml of blood.
Migration assay. Bone marrow MNCs were isolated by Ficoll separation, and migration assays were performed in Transwell chambers (Costar) as previously described 28 . Briefly, 2 × 10 5 bone marrow MNCs were added to the upper transwell for migration toward 125 ng/ml CXCL12 (PeproTech, Rocky Hill, NJ, USA) for 2 h in full RPMI 1640 medium (Gibco) containing 10% FCS. Following migration, cells from the upper well (referred to as non-migrating cells) and cells from the bottom chamber (referred to as migrating cells) were stained for LSK or LSK and EPCR expression and analyzed by flow cytometry.
Adhesion assay. Non-tissue culture 6-well plates (Corning) were coated with 25 µg/ml fibronectin (Sigma) and 2.5 µg/ml CXCL12 (PeproTech, Rocky Hill, NJ, USA) overnight at 4 °C. The plates were subsequently washed with PBS and blocked with 2% BSA for 30 min at room temperature. Bone marrow MNCs (5 × 10 6 ) cells were seeded in RPMI 1640 medium (Gibco) containing 10% FCS and then allowed to adhere to the coated plates for 2 h at 37 °C. Nonadherent cells were collected by gently rinsing with the medium. To collect adherent cells, plates were gently washed three times with PBS followed by incubation with cell dissociation buffer (Gibco, Carlsbad, CA) and vigorous rinsing with PBS. The cells were then stained for LSK or EPCR and LSK expression and analyzed by flow cytometry.
CXCL12 ELISA. Levels of functional CXCL12 in plasma and bone marrow were determined as described 28 . Total protein content in bone marrow fluid was quantified by Bradford assay, and CXCL12 concentration in bone marrow fluid was normalized to protein content. sEPCR ELISA. Mouse sEPCR ELISA (Biotechnology Systems, M7888) was used to determine sEPCR content following thrombin stimulation in vitro. In some experiments, total bone marrow cells were lineage depleted using mouse lineage depletion kit (BD) according to the manufacturer's instructions. The lineage depleted cell fraction (5 × 10 6 cells) was stimulated with either PBS or thrombin (1 U/ml) for 45 min at 37 °C. Following incubation, supernatants were collected to measure sEPCR. To determine sEPCR content following thrombin treatment in vivo, wild-type and F2r −/− mice were treated with thrombin and sacrificed 1 h later. Bones were flushed in 300 µl PBS, and supernatants were collected to measure sEPCR based on an sEPCR standard curve and normalization to total protein in the sample, as determined using the Bradford reagent. aPC and FVIIa inactivation. Mouse activated protein C was active-site blocked by incubation with 100 µM 1,5-DNS-GGACK (EMD 251700, Calbiochem) for 3 d at 4 °C, followed by extensive dialysis against HEPES buffered saline (HBS). The protein concentration was determined and loss of catalytic activity toward a chromogenic substrate (Spectozyme aPC) was verified. FVIIa inactivation was performed as previously described 64 .
